BE study results Evaluation [Study As­sess­ment]

posted by Vaibhav – India, 2022-06-14 22:57 (1118 d 18:32 ago) – Posting: # 23057
Views: 3,581

Dear All,
This is my first post on this forum. Please ignore any mistake.
In 2016, we did BE study of Lenalidomide 25 mg capsule for EMA submission.

Enrolled N =54
Completed N =52

Now are planning to conduct another BE study with same Test formulation (used in EMA) for ANVISA.

Below are the EMA study results.

1. Cmax
T/R 104.13
CI: 97.89-110.77
CV: 18.97
Power: 99.99

2. AUCo-t
T/R 102.20
CI: 100.51- 103.92
CV: 5.08
Power:100

My question is can we proceed with sample size i.e. 54 or should re-calculate sample size based on EMA study results?

T/R- 105%
Power- 90%
CV- Approx. 19%

What could be the right approach for sample size calculation for ANVISA submission study?

Please let us know if you need more information.

Complete thread:

UA Flag
Activity
 Admin contact
23,428 posts in 4,929 threads, 1,680 registered users;
55 visitors (0 registered, 55 guests [including 20 identified bots]).
Forum time: 17:30 CEST (Europe/Vienna)

No matter what side of the argument you are on,
you always find people on your side
that you wish were on the other.    Thomas Berger

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz
HTML5